Universal Biosensors Full Year 2022 Earnings: Misses Expectations
Universal Biosensors (ASX:UBI) Full Year 2022 Results
Key Financial Results
Revenue: AU$4.52m (down 22% from FY 2021).
Net loss: AU$26.9m (loss widened by 156% from FY 2021).
AU$0.14 loss per share (further deteriorated from AU$0.059 loss in FY 2021).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Universal Biosensors Revenues and Earnings Miss Expectations
Revenue missed analyst estimates by 22%. Earnings per share (EPS) also missed analyst estimates by 109%.
Looking ahead, revenue is forecast to grow 59% p.a. on average during the next 2 years, compared to a 12% growth forecast for the Medical Equipment industry in Australia.
Performance of the Australian Medical Equipment industry.
The company's shares are down 11% from a week ago.
Risk Analysis
Before you take the next step you should know about the 4 warning signs for Universal Biosensors that we have uncovered.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Join A Paid User Research Session
You’ll receive a US$30 Amazon Gift card for 1 hour of your time while helping us build better investing tools for the individual investors like yourself. Sign up here
